Home » Healthcare » Pharmaceuticals » Pompe Disease Therapeutics Market

Pompe Disease Therapeutics Market

Global Pompe Disease Therapeutics Market By Therapy Type (Enzyme Replacement Therapy (ERT), Recombinant Enzymes, Long-Acting ERT, Novel ERT Formulations, Gene Therapy, Viral Vector-Based Gene Therapy, Non-Viral Gene Therapy, Small Molecule Therapies, Chaperone Therapies, Substrate Reduction Therapies (SRT), Supportive Therapies, Symptomatic Treatment, Nutritional Support) By Route of Administration (Intravenous (IV) Administration, Oral Administration) By End-User (Hospitals and Clinics, Specialty Clinics, Home Care Settings) – Growth, Future Prospects & Competitive Analysis, 2024-2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2019-2022
Base Year	2023
Forecast Period	2024-2032
Pompe Disease Therapeutics Market Size 2023	USD 1584.2 million
Pompe Disease Therapeutics Market, CAGR	5.00%
Pompe Disease Therapeutics Market Size 2032	USD 2457.61 million

Market Insights

Between 2024 and 2032, the global market for Pompe disease therapeutics is projected to expand at a compound annual growth rate (CAGR) of 5.00%, from an estimated USD 1584.2 million in 2023 to USD 2457.61 million in 2032.
The largest category is enzyme replacement therapy (ERT). Gene therapy, on the other hand, is expected to grow at a strong CAGR.
The oral administration category will expand rapidly.
Throughout the projected period, the CAGR for hospitals and clinics is anticipated to be the highest.
Asia Pacific controlled the Pompe disease therapeutics market.
Regarding the market share of Pompe disease therapeutics, Europe is expected to come second.
North America is expected to experience the fastest growth in the Pompe disease therapeutics industry.
Developments in gene therapy and enzyme replacement therapy (ERT) are propelling the global expansion of the Pompe disease therapeutics market.
Regulations favoring orphan pharmaceuticals and raising public awareness of uncommon diseases could expand the market for therapeutics for Pompe disease.

Executive Summary

Market Definition

The pharmaceutical and biotechnology sector segment dedicated to the creation, manufacturing, and marketing of medications especially intended to manage and treat Pompe’s illness is known as the Pompe disease Therapeutics Market. Pompe disease is a rare inherited lysosomal storage illness characterized by a loss of the enzyme acid alpha-glucosidase (GAA). It is also referred to as glycogen storage disease type II or acid maltase deficiency. This enzyme deficit causes glycogen to build up in a variety of tissues, especially the muscles, which eventually results in breathing troubles and gradual muscle weakening.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Overview

It is predicted that the Pompe disease therapeutics industry will continue its upward trajectory between 2024 and 2032, growing at a compound annual growth rate (CAGR) of 5.00%. From its projected USD 1584.2 million in 2023 to USD 2457.61 million in 2032, the market will continue to grow.

Launching new medications and continuing to use long-term therapy are major factors contributing to the market’s expansion. Heart defects, respiratory issues, and skeletal muscle are the main effects of Pompe disease, a rare disease that can have either an early infantile or late beginning. One in 40,000 Americans, for example, suffer from Pompe disease, according to a National Institutes of Health report from April 2022. Furthermore, patients from East Asian and African backgrounds with traditional infantile-onset Pompe disease had greater proportions of pathogenic or potentially pathogenic variations (PLPVs), according to a June 2021 research report. According to the same source, the total carrier frequency (CF) and anticipated genetic prevalence (pGP) in the general population were 1 in 77 (1.3%) and 1:23,232, respectively. Therefore, it is projected that during the projection period, the increasing prevalence of Pompe illness will spur market expansion.

It is projected that the introduction of new medications will increase demand for Pompe disease therapy, thus propelling market expansion. Moreover, as Pompe disease typically results in death if left untreated, increasing R&D spending internationally will encourage research into innovative medicines and the treatment of the illness. For example, using technology created at Genethon, the business Spark Therapeutics started a gene therapy clinical trial for late-onset Pompe illness in February 2021, which was initiated by Genethon. Furthermore, since gene therapy and enzyme replacement treatment are being developed at a rapid pace to treat Pompe disease, these developments may present a significant growth opportunity for the market during the projection period.

Segmentation by Therapy Type

Enzyme replacement therapy (ERT) is the market leader in terms of therapy type. Due to its position as the main therapeutic option, enzyme replacement therapy (ERT) is in high demand in the Pompe disease therapeutics Market. In order to reduce symptoms and enhance quality of life, ERT attempts to replenish the missing enzyme (acid alpha-glucosidase) in individuals with Pompe disease.
The gene therapy category will exhibit a sizable CAGR during the projected period. Due to its ability to treat the disease by treating its underlying genetic etiology, gene therapy is becoming more and more popular in the Pompe disease therapeutics Market. The goal of gene therapy is to replace the defective gene with functional copies in order to produce more enzymes and reduce symptoms.
Other therapy types, including small molecule therapies and supportive therapies, also support the need for Pompe disease therapeutics.

Segmentation by Route of Administration

Oral administration is considered the best route of administration. Patients’ choice for non-invasive therapies is driving up demand for oral administration options in the Pompe disease therapeutics market. For Pompe disease patients who need long-term care for their condition, oral treatments are convenient and may enhance treatment compliance and quality of life.
The intravenous (IV) administration category will likely register a significant CAGR during forecasting. Since intravenous (IV) administration is the predominant method of administering enzyme replacement therapy (ERT), the demand for IV administration in the Pompe Disease Therapeutics Market is very strong. Direct and effective distribution of therapeutic enzymes is ensured by IV injection, which is essential for effectively controlling Pompe disease and reducing its symptoms.

Segmentation by End-User

The hospitals and clinics category is projected to grow faster over the projection period. Hospitals and clinics, which offer specialized care and administer therapies, including gene therapy and enzyme replacement therapy (ERT), are important demand centers in the Pompe disease therapeutics market. They provide extensive medical facilities and knowledge necessary for properly managing patients with Pompe disease and tracking therapy results.
Other end-users, including specialty clinics and home care settings, also influence the need for Pompe disease therapeutics.

Segmentation by Region

The Asia Pacific leads the Pompe disease therapeutics industry. This is due to the rising demand for Pompe disease therapeutics from Asia Pacific countries such as China, India, Australia, and others countries.
Europe is estimated to rank second in the market size of Pompe disease therapeutics.
It is anticipated that the Pompe disease therapeutics market in North America will grow quickly.
The remaining need for pompe disease therapeutics is met by regions including Latin America, the Middle East, and Africa.

The Pompe disease therapeutics market continues to expand because of strategic alliances and collaborations. Pharmaceutical businesses, biotech companies, and academic institutions collaborate to speed the development of novel medicines by combining their resources, knowledge, and technological capabilities. These partnerships speed up regulatory approvals, improve research capacities, and enable clinical trials. Companies can share the costs and risks of research and development through joint ventures and mergers, which creates more strong and diverse pharmaceutical pipelines. Additionally, collaborations with patient advocacy groups guarantee a deeper comprehension of patients’ requirements, enhancing the effectiveness of treatments and patient outcomes, which in turn promotes market expansion and advances Pompe disease treatment options.

It is anticipated that pompe disease therapeutics sales in Asia Pacific will surpass those in the entire world. Pompe Disease Therapeutics are becoming much more in demand throughout the Asia Pacific, especially in specialist clinics. The expanding healthcare infrastructure, better diagnostic tools, and growing knowledge of uncommon genetic illnesses are the main drivers of this growth. Specialty clinics are better suited to identify and manage Pompe’s illness because they have specialized knowledge and cutting-edge equipment. Furthermore, rising healthcare expenditures and encouraging policies make cutting-edge therapies more accessible, which drives up demand for specialty clinics in this area.

It is projected that the Pompe disease therapeutics market will develop at the fastest rate in the North American region. Numerous pharmaceutical businesses, the increasing number of new drug launches, rising R&D costs, and patient preferences for cutting-edge treatments, new product launches, and technical breakthroughs are all contributing reasons to the expansion. As of the March 2021 International Journal of Neonatal Screening research report, California screened more than 500,000 infants, with a birth frequency of 1 in every 25,200 in 2021. Moreover, a research journal published in November 2021 estimates that 1.0% of the population in the United States, Montreal, and Canada has late-onset Pompe disease (LOPD). The increased frequency of Pompe’s illness is therefore anticipated to support market expansion in the North American area.

Key Highlights of the Report

The global Pompe disease therapeutics market is segmented by therapy type, route of administration, end-user, and region. As far as the therapy type is concerned, enzyme replacement therapy (ERT) is the market spearhead. Oral administration is the top route of the administration category. Throughout the forecast period, the category of hospitals and clinics is expected to grow at the greatest CAGR. Asia Pacific is seeing the most growth in the Pompe disease therapeutics market.

The Pompe disease therapeutics market is growing at a fast rate due to the rising frequency of genetic disorders. Improved diagnostic tools, like sophisticated genetic testing and neonatal screening, allow for the earlier and more precise identification of Pompe disease. The increased need for efficient therapies is a result of these increased diagnostic rates. More cases have also been identified as a result of increased awareness among the public and medical experts. The need for specialist treatments, such as enzyme replacement and gene therapies, increases as more people are identified with Pompe disease and associated genetic illnesses. This encourages market expansion and encourages ongoing investment in research and development.

It is anticipated that Asia Pacific will hold the biggest global market share for Pompe disease therapeutics. Enhancing patient convenience, developments in home-based healthcare technologies, and the growing demand for ongoing, easily accessible therapy are propelling the demand for Pompe Disease Therapeutics in home care settings throughout Asia Pacific. Optional home care enhances life quality, lowers hospital stays, and helps with continuing Pompe disease treatment. In addition, it is projected that the market in North America will grow at the quickest rate. The escalating incidence of Pompe disease, increasing federal programs in the United States, acquisitions and partnerships among significant competitors, a high concentration of manufacturers or market players, and significant product launches are some of the factors contributing to the growth of the Pompe disease therapeutics market in North America.

Which Key Factors Are Driving The Global Pompe Disease Therapeutics Market?

The increased funding for biotechnology, the expansion of newborn screening programs, and the advancements in drug delivery technologies are driving the need for therapeutics for Pompe disease.

What Are The Main Challenges Confronting The Global Pompe Disease Therapeutics Market?

The most significant challenges confronting the Pompe disease therapeutics market are the high cost of enzyme replacement therapy (ERT) and the prolonged regulatory and development processes.

What Market Opportunities Exist For Pompe Disease Therapeutics Globally?

The Pompe disease therapeutics market is expanding due to a number of factors, including the rise in genetic illnesses worldwide, partnerships with academic institutions, and advancements in biopharmaceutical manufacturing.

Market Drivers

Developments in Medical Research and Biotechnology

Medical research and biotechnology developments are two major factors propelling the Pompe disease therapeutics market’s expansion. More efficient and focused therapy options are now available because of developments in gene and enzyme replacement therapies. Advances in genetic engineering, like CRISPR, increase the likelihood of permanent remedies by repairing the underlying genetic flaws. New small molecule treatments and pharmacological chaperones are developed as a result of a better understanding of illness mechanisms. Modern diagnostic technologies also make early detection and intervention possible, which greatly enhances patient outcomes. Together, these developments quicken the pace of therapeutic research, boost the effectiveness of existing treatments, and broaden the prospects for treatments for Pompe disease.

Market Restraints

Lack of Awareness and Diagnosis

The Pompe disease therapeutics market is heavily constrained in its expansion by a lack of diagnosis and awareness. Because Pompe disease is uncommon and its symptoms are complex, many patients go untreated or are initially misdiagnosed. This keeps patients from receiving the right medicines and postpones the start of treatment. The problem is made worse by healthcare practitioners’ lack of knowledge about Pompe disease, which causes them to underestimate its prevalence and put off using effective management techniques. To improve early diagnosis, enable prompt intervention, and support market expansion for Pompe disease therapies, there is a need for more education and public awareness among healthcare professionals and the general public.

Opportunities

Increasing Funding for Research on Rare Diseases

The Pompe disease therapeutics market has a lot of prospects due to the growing investment in rare illness research. The development of novel medicines, such as gene therapy and enzyme replacement, is accelerated by increased funding from governments, pharmaceutical firms, and non-profit groups. These investments fund in-depth studies and clinical studies that advance the understanding of Pompe’s illness and pave the way for more specialized and potent treatments. Financial support also makes it easier for novel treatments to get market access and regulatory clearances. As a result, more patients gain from cutting-edge therapies, propelling industry expansion and fostering constant advancement in Pompe disease management approaches.

Competitive Landscape

Key Players

The highly competitive global market for Pompe disease therapeutics is dominated by a number of significant players. A handful of the top market players are shown below, together with their respective market shares:

Amicus Therapeutics, Inc. (U.S.)
Audentes Therapeutics (U.S.)
Novartis AG (Switzerland)
Fresenius Kabi AG (Germany)
Akorn Incorporated (U.S.)
Teva Pharmaceutical Industries Ltd (Israel)
Mylan N.V (U.S.)
Johnsons & Johnsons Services Inc (U.S.)
F. Hoffman-La Roche Ltd. (Switzerland)
Danaher (U.S.)
B.D. (U.S.)
Chembio Diagnostics (U.S.)
EKF Diagnostics (U.K.)
Trinity Biotech plc (Ireland)
Instrumentation Laboratory (U.S.)
Nova Biomedical (U.S.)
PTS Diagnostics (U.S.)
Sekisui Diagnostics (U.S.)
Thermo Fisher Scientific (U.S.)
bioMérieux S.A. (France)
Others

In order to stay competitive, these organizations give priority to product innovation, expansion of their distribution channels, and mergers and acquisitions.

By creating cutting-edge ideas and goods, the foremost manufacturers in the global market for Pompe disease therapeutics consistently strive to stay one step ahead of the competition.

In August 2023, The Medicines and Healthcare Products Regulatory Agency (MHRA) approved Amicus Therapeutics’ Pombiliti+ Opfolda for sale. The medication is intended for use in patients with late-onset Pompe disease. In addition, Pombiliti + Opfolda reimbursement was approved by the National Institute for Health and Care Excellence (NICE) for the National Health Service (NHS) in England and Wales. By addressing unmet medical needs, these strategic collaborations strive to provide patients with novel therapies more quickly.

In February 2022, Maze Therapeutics, a company that uses genetic insights to create novel precision medications, released new preclinical data in favor of the development of MZE001, a medication intended to treat Pompe disease by inhibiting muscle glycogen synthase (GYS1) and lowering pathologic glycogen accumulation.

How are Companies Performing in the Pompe Disease Therapeutics Market?

Due to a number of significant factors, companies in the Pompe disease therapeutics sector are performing well. To maintain their position in the market, the leading companies in the Pompe disease therapeutics sector are implementing innovations. For example, the US Food and Drug Administration (FDA) accepted Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) 65 mg capsules in September 2023, both of which are produced by Amicus Therapeutics, a biopharmaceutical firm based in the United States. Adults with late-onset Pompe disease (LOPD) who weigh at least 40 kg are intended to get this two-component treatment. Pombiliti and Opfolda together represent a novel combination: Pombiliti is a recombinant human GAA enzyme (rhGAA) engineered for enhanced absorption into muscle cells, while Opfolda functions as an enzyme stabilizer to maintain the enzyme in circulation. The importance of scientific and medical achievements is highlighted by this FDA approval.

Significant companies in the Pompe disease sector are concentrating on creating treatments like enzyme replacement therapy (ERT) that can assist patients with severe symptoms like respiratory problems and muscular failure who have late-onset Pompe disease. For example, in August 2021, the European Commission acknowledged Nexviazyme, a pharmaceutical and healthcare company based in France, for the administration of patients one year of age and older with late-onset Pompe disease, a debilitating and severe muscular illness that restricts breathing and movement.

The US biopharmaceutical company Asklepios BioPharmaceutical Inc., which is experienced in the development and production of gene therapies for Pompe disease, and the Swedish company Hansa Biopharma AB, which is proficient in enzyme technology for rare immunological conditions, formed a partnership in January 2022 to evaluate the possibility of using imlifidase as a pre-treatment prior to the administration of AskBio’s gene therapy for Pompe disease. This entails a pre-clinical and clinical feasibility program for individuals who already have anti-adeno-associated virus (AAV) neutralizing antibodies (NAbs). According to the terms of the agreement, AskBio has the exclusive right to a full research and commercialization agreement depending on the outcomes of a preliminary Phase I/II study. Hansa will receive a $5 million payment upon its implementation.

Summary of Key Findings

The demand for therapies for Pompe disease is influenced by the growth of genetic testing services and the integration of technology in healthcare.
The market is segmented by therapy type, route of administration, end-user, and region.
In the market, the most prevalent therapy type is enzyme replacement therapy (ERT).
Oral administration is the foremost route of the administration category.
Hospitals and clinics are expected to grow fastest in terms of CAGR during the forecast period.
In terms of market development, Asia Pacific is a leader; the market is highly competitive with key players including Amicus Therapeutics, Inc (U.S.), Audentes Therapeutics (U.S.), Novartis AG (Switzerland), Fresenius Kabi AG (Germany), Akorn Incorporated (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Mylan N.V (U.S.), Johnsons & Johnsons Services Inc (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), Danaher (U.S.), B.D. (U.S.), Chembio Diagnostics (U.S.), EKF Diagnostics (U.K.), Trinity Biotech plc (Ireland), Instrumentation Laboratory (U.S.), Nova Biomedical (U.S.), PTS Diagnostics (U.S.), Sekisui Diagnostics (U.S.), Thermo Fisher Scientific (U.S.), bioMérieux S.A. (France), and Others.

Future Outlook

The Pompe disease therapeutics industry is expected to increase significantly in Asia Pacific, and its outlook is positive worldwide.
The market will continue growing due to several factors, such as the adoption of precision medicine and educational programs for healthcare professionals.
The main obstacle influencing the market for therapeutics for Pompe’s illness is a lack of awareness among healthcare providers.
Developing new products, reaching a wider market, and maintaining competitive prices are all necessary for major businesses to stay ahead of the competition.

How the Credence Research Pompe Disease Therapeutics Market Report Can Help CXOs

The Credence Research Pompe Disease Therapeutics Market Report provides CXOs with an extensive market overview and comprises the following:

Market size and growth forecast: The study offers comprehensive market estimations for Pompe disease therapeutics globally, broken down by therapy type, route of administration, end-user, and region. Furthermore, the report includes market forecasts through 2032, derived from key drivers and trends.
Market segmentation: The Pompe disease therapeutics market is divided into segments by therapy type, route of administration, end-user, and region in the research report. This segmentation helps CXOs understand the market and the opportunities inside each area in great depth.
Competitive landscape: The study report provides a thorough analysis of the leading businesses in the Pompe disease therapeutics sector, together with details on their revenue streams, product lines, and business strategies. With this information, CXOs can assess and identify their competitors.
Key trends and drivers: The study report analyzes and highlights the key developments and elements driving the market for Pompe disease therapeutics. CXOs can utilize this information to make well-informed choices regarding their plans and investments.

The Credence Research Pompe Disease Therapeutics Market Report provides CXOs with insights that they may utilize to:

Identify growth opportunities: This analysis is likely to help CXOs find fresh growth prospects in the Pompe disease therapeutics sector. For example, the research recognizes the increasing requirement for Pompe disease therapeutics from hospitals and clinics as a crucial opportunity.
Make informed investment decisions: The study aids CXOs in making informed decisions about Pompe disease therapeutics. For example, it delivers information on the key variables to consider while picking pompe disease therapeutics solutions and evaluating suppliers.
Develop competitive strategies: CXOs can utilize the research report to establish competitive strategies for their Pompe disease therapeutics firms. The study paper explores the primary tactics employed by Pompe disease therapeutics providers to set themselves apart from their rivals.
Track market developments: By tracking market advancements, this research report could assist CXOs in remaining ahead of the curve. For example, it provides information about the latest advancements and patterns in the Pompe disease therapeutics industry.

The Credence Research Pompe Disease Therapeutics Market Report is helpful for CXOs who want to learn more about the market and identify potential opportunities.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Segmentation

By Therapy Type
- Enzyme Replacement Therapy (ERT)
  - Recombinant Enzymes
  - Long-Acting ERT
  - Novel ERT Formulations
- Gene Therapy
  - Viral Vector-Based Gene Therapy
  - Non-Viral Gene Therapy
- Small Molecule Therapies
  - Chaperone Therapies
  - Substrate Reduction Therapies (SRT)
- Supportive Therapies
  - Symptomatic Treatment
  - Nutritional Support
- By Route of Administration
  - Intravenous (IV) Administration
  - Oral Administration
- By End-User
  - Hospitals and Clinics
  - Specialty Clinics
  - Home Care Settings
- By Region
  - North America
    - U.S.
    - Canada
    - Mexico
  - Europe
    - Germany
    - France
    - UK.
    - Italy
    - Spain
    - Rest of Europe
  - Asia Pacific
    - China
    - Japan
    - India
    - South Korea
    - South-east Asia
    - Rest of Asia Pacific
  - Latin America
    - Brazil
    - Argentina
    - Rest of Latin America
  - Middle East & Africa
    - GCC Countries
    - South Africa
    - The Rest of the Middle East and Africa

Adjacent Markets

Several adjacent markets in the Pompe disease therapeutics market have high revenue growth opportunities. The key adjacent markets for the Pompe disease therapeutics market –

Adjacent Markets
Glycogen Storage Disorders (GSDs)	Lysosomal Storage Disorders (LSDs)	Enzyme Replacement Therapy (ERT)
Gene Therapy	Metabolic Disorders	Muscular Dystrophies
Mitochondrial Diseases	Neuromuscular Diseases	Chronic Inflammatory Diseases

1. Preface

1.1. Report Description

1.1.1. Purpose of the Report

1.1.2. Target Audience

1.1.3. USP and Key Offerings

1.2. Research Scope

1.3. Market Introduction

2. Executive Summary

2.1. Market Snapshot: Global Pompe Disease Therapeutics Market

2.1.1. Global Pompe Disease Therapeutics Market, By Therapy Type

2.1.2. Global Pompe Disease Therapeutics Market, By Route of Administration

2.1.3. Global Pompe Disease Therapeutics Market, By End-User

2.1.4. Global Pompe Disease Therapeutics Market, By Region

2.2. Insights from Primary Respondents

3. Market Dynamics & Factors Analysis

3.1. Introduction

3.1.1. Global Pompe Disease Therapeutics Market Value, 2019-2032, (US$ Mn)

3.1.2. Y-o-Y Growth Trend Analysis

3.2. Market Dynamics

3.2.1. Pompe Disease Therapeutics Market Drivers

3.2.2. Pompe Disease Therapeutics Market Restraints

3.2.3. Pompe Disease Therapeutics Market Opportunities

3.2.4. Major Pompe Disease Therapeutics Industry Challenges

3.3. Growth and Development Patterns

3.4. Investment Feasibility Analysis

3.5. Market Opportunity Analysis

3.5.1. Therapy Type

3.5.2. Route of Administration

3.5.3. End-User

3.5.4. Geography

4. Market Competitive Landscape Analysis

4.1. Company Market Share Analysis, 2023

4.1.1. Global Pompe Disease Therapeutics Market: Company Market Share, Value 2023

4.1.2. Global Pompe Disease Therapeutics Market: Top 6 Company Market Share, Value 2023

4.1.3. Global Pompe Disease Therapeutics Market: Top 3 Company Market Share, Value 2023

4.2. Global Pompe Disease Therapeutics Market: Company Revenue Share Analysis, 2023

4.3. Company Assessment Metrics, 2023

4.3.1. Stars

4.3.2. Emerging Leaders

4.3.3. Pervasive Players

4.3.4. Participants

4.4. Startups/ SMEs Assessment Metrics, 2023

4.4.1. Progressive Companies

4.4.2. Responsive Companies

4.4.3. Dynamic Companies

4.4.4. Starting Blocks

4.5. Strategic Development

4.5.1. Acquisition and Mergers

4.5.2. New Product Launch

4.5.3. Regional Expansion

4.5.4. Partnerships

4.6. Key Player Product Matrix

4.7. Potential for New Players in the Global Pompe Disease Therapeutics Market

5. Premium Insights

5.1. STAR (Situation, Task, Action, Results) Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Threat of New Entrants

5.2.2. Bargaining Power of Buyers/Consumers

5.2.3. Bargaining Power of Suppliers

5.2.4. Threat of Substitute Types

5.2.5. Intensity of Competitive Rivalry

5.3. PESTEL Analysis

5.3.1. Political Factors

5.3.2. Economic Factors

5.3.3. Social Factors

5.3.4. Technological Factors

5.3.5. Environmental Factors

5.3.6. Legal Factors

5.4. Key Market Trends

5.4.1. Demand Side Trends

5.4.2. Supply Side Trends

5.5. Value Chain Analysis

5.6. Technology Analysis

5.6.1. Research and development in the global market

5.6.2. Patent Analysis

5.6.3. Emerging technologies and their potential disruption to the market

5.7. Consumer Behaviour Analysis

5.7.1. Consumer Preferences and Expectations

5.7.2. Factors Influencing Consumer Buying Decisions

5.7.2.1. North America

5.7.2.2. Europe

5.7.2.3. Asia Pacific

5.7.2.4. Latin America

5.7.2.5. Middle East and Africa

5.7.3. Consumer Pain Points

5.8. Analysis and Recommendations

5.9. Adjacent Market Analysis

6. Market Positioning of Key Players, 2023

6.1. Company market share of key players, 2023

6.2. Competitive Benchmarking

6.3. Market Positioning of Key Vendors

6.4. Geographical Presence Analysis

6.5. Major Strategies Adopted by Key Players

6.5.1. Key Strategies Analysis

6.5.2. Mergers and Acquisitions

6.5.3. Partnerships

6.5.4. Product Launch

6.5.5. Geographical Expansion

6.5.6. Others

7. Impact Analysis of COVID 19 and Russia – Ukraine War on Pompe Disease Therapeutics Market

7.1. Ukraine-Russia War Impact

7.1.1. Uncertainty and Economic Instability

7.1.2. Supply chain disruptions

7.1.3. Regional market shifts

7.1.4. Shift in government priorities

7.2. COVID-19 Impact Analysis

7.2.1. Supply Chain Disruptions

7.2.2. Demand Fluctuations

7.2.3. Shift in Product Mix

7.2.4. Reduced Industrial Activity

7.2.5. Regional Impact Analysis

7.2.5.1. North America

7.2.5.2. Europe

7.2.5.3. Asia Pacific

7.2.5.4. Latin America

7.2.5.5. Middle East and Africa

8. Global Pompe Disease Therapeutics Market, By Therapy Type

8.1. Global Pompe Disease Therapeutics Market Overview, by Therapy Type

8.1.1. Global Pompe Disease Therapeutics Market Revenue Share, By Therapy Type, 2023 Vs 2032 (in %)

8.2. Enzyme Replacement Therapy (ERT)

8.2.1. Global Pompe Disease Therapeutics Market, By Enzyme Replacement Therapy (ERT), By Region, 2019-2032 (US$ Mn)

8.2.2. Market Dynamics for Enzyme Replacement Therapy (ERT)

8.2.2.1. Drivers

8.2.2.2. Restraints

8.2.2.3. Opportunities

8.2.2.4. Trends

8.3. Gene Therapy

8.3.1. Global Pompe Disease Therapeutics Market, By Gene Therapy, By Region, 2019-2032 (US$ Mn)

8.3.2. Market Dynamics for Gene Therapy

8.3.2.1. Drivers

8.3.2.2. Restraints

8.3.2.3. Opportunities

8.3.2.4. Trends

8.4. Small Molecule Therapies

8.4.1. Global Pompe Disease Therapeutics Market, By Small Molecule Therapies, By Region, 2019-2032 (US$ Mn)

8.4.2. Market Dynamics for Small Molecule Therapies

8.4.2.1. Drivers

8.4.2.2. Restraints

8.4.2.3. Opportunities

8.4.2.4. Trends

8.5. Supportive Therapies

8.5.1. Global Pompe Disease Therapeutics Market, By Supportive Therapies, By Region, 2019-2032 (US$ Mn)

8.5.2. Market Dynamics for Supportive Therapies

8.5.2.1. Drivers

8.5.2.2. Restraints

8.5.2.3. Opportunities

8.5.2.4. Trends

9. Global Pompe Disease Therapeutics Market, By Route of Administration

9.1. Global Pompe Disease Therapeutics Market Overview, by Route of Administration

9.1.1. Global Pompe Disease Therapeutics Market Revenue Share, By Route of Administration, 2023 Vs 2032 (in %)

9.2. Intravenous (IV) Administration

9.2.1. Global Pompe Disease Therapeutics Market, By Intravenous (IV) Administration, By Region, 2019-2032 (US$ Mn)

9.2.2. Market Dynamics for Intravenous (IV) Administration

9.2.2.1. Drivers

9.2.2.2. Restraints

9.2.2.3. Opportunities

9.2.2.4. Trends

9.3. Oral Administration

9.3.1. Global Pompe Disease Therapeutics Market, By Oral Administration, By Region, 2019-2032 (US$ Mn)

9.3.2. Market Dynamics for Oral Administration

9.3.2.1. Drivers

9.3.2.2. Restraints

9.3.2.3. Opportunities

9.3.2.4. Trends

10. Global Pompe Disease Therapeutics Market, By End-User

10.1. Global Pompe Disease Therapeutics Market Overview, by End-User

10.1.1. Global Pompe Disease Therapeutics Market Revenue Share, By End-User, 2023 Vs 2032 (in %)

10.2. Hospitals and Clinics

10.2.1. Global Pompe Disease Therapeutics Market, By Hospitals and Clinics, By Region, 2019-2032 (US$ Mn)

10.2.2. Market Dynamics for Hospitals and Clinics

10.2.2.1. Drivers

10.2.2.2. Restraints

10.2.2.3. Opportunities

10.2.2.4. Trends

10.3. Specialty Clinics

10.3.1. Global Pompe Disease Therapeutics Market, By Specialty Clinics, By Region, 2019-2032 (US$ Mn)

10.3.2. Market Dynamics for Specialty Clinics

10.3.2.1. Drivers

10.3.2.2. Restraints

10.3.2.3. Opportunities

10.3.2.4. Trends

10.4. Home Care Settings

10.4.1. Global Pompe Disease Therapeutics Market, By Home Care Settings, By Region, 2019-2032 (US$ Mn)

10.4.2. Market Dynamics for Home Care Settings

10.4.2.1. Drivers

10.4.2.2. Restraints

10.4.2.3. Opportunities

10.4.2.4. Trends

11. Global Pompe Disease Therapeutics Market, By Region

11.1. Global Pompe Disease Therapeutics Market Overview, by Region

11.1.1. Global Pompe Disease Therapeutics Market, By Region, 2023 Vs 2032 (in%)

11.2. Therapy Type

11.2.1. Global Pompe Disease Therapeutics Market, By Therapy Type, 2019-2032 (US$ Mn)

11.3. Route of Administration

11.3.1. Global Pompe Disease Therapeutics Market, By Route of Administration, 2019-2032 (US$ Mn)

11.4. End-User

11.4.1. Global Pompe Disease Therapeutics Market, By End-User, 2019-2032 (US$ Mn)

12. North America Pompe Disease Therapeutics Market Analysis

12.1. Overview

12.1.1. Market Dynamics for North America

12.1.1.1. Drivers

12.1.1.2. Restraints

12.1.1.3. Opportunities

12.1.1.4. Trends

12.2. North America Pompe Disease Therapeutics Market, by Therapy Type, 2019-2032(US$ Mn)

12.2.1. Overview

12.2.2. SRC Analysis

12.3. North America Pompe Disease Therapeutics Market, by Route of Administration, 2019-2032(US$ Mn)

12.3.1. Overview

12.3.2. SRC Analysis

12.4. North America Pompe Disease Therapeutics Market, by End-User, 2019-2032(US$ Mn)

12.4.1. Overview

12.4.2. SRC Analysis

12.5. North America Pompe Disease Therapeutics Market, by Country, 2019-2032 (US$ Mn)

12.5.1. North America Pompe Disease Therapeutics Market, by Country, 2023 Vs 2032 (in%)

12.5.2. U.S.

12.5.3. Canada

12.5.4. Mexico

13. Europe Pompe Disease Therapeutics Market Analysis

13.1. Overview

13.1.1. Market Dynamics for Europe

13.1.1.1. Drivers

13.1.1.2. Restraints

13.1.1.3. Opportunities

13.1.1.4. Trends

13.2. Europe Pompe Disease Therapeutics Market, by Therapy Type, 2019-2032(US$ Mn)

13.2.1. Overview

13.2.2. SRC Analysis

13.3. Europe Pompe Disease Therapeutics Market, by Route of Administration, 2019-2032(US$ Mn)

13.3.1. Overview

13.3.2. SRC Analysis

13.4. Europe Pompe Disease Therapeutics Market, by End-User, 2019-2032(US$ Mn)

13.4.1. Overview

13.4.2. SRC Analysis

13.5. Europe Pompe Disease Therapeutics Market, by Country, 2019-2032 (US$ Mn)

13.5.1. Europe Pompe Disease Therapeutics Market, by Country, 2023 Vs 2032 (in%)

13.5.2. UK

13.5.3. France

13.5.4. Germany

13.5.5. Italy

13.5.6. Spain

13.5.7. Benelux

13.5.8. Russia

13.5.9. Rest of Europe

14. Asia Pacific Pompe Disease Therapeutics Market Analysis

14.1. Overview

14.1.1. Market Dynamics for Asia Pacific

14.1.1.1. Drivers

14.1.1.2. Restraints

14.1.1.3. Opportunities

14.1.1.4. Trends

14.2. Asia Pacific Pompe Disease Therapeutics Market, by Therapy Type, 2019-2032(US$ Mn)

14.2.1. Overview

14.2.2. SRC Analysis

14.3. Asia Pacific Pompe Disease Therapeutics Market, by Route of Administration, 2019-2032(US$ Mn)

14.3.1. Overview

14.3.2. SRC Analysis

14.4. Asia Pacific Pompe Disease Therapeutics Market, by End-User, 2019-2032(US$ Mn)

14.4.1. Overview

14.4.2. SRC Analysis

14.5. Asia Pacific Pompe Disease Therapeutics Market, by Country, 2019-2032 (US$ Mn)

14.5.1. Asia Pacific Pompe Disease Therapeutics Market, by Country, 2023 Vs 2032 (in%)

14.5.2. China

14.5.3. Japan

14.5.4. India

14.5.5. South Korea

14.5.6. South East Asia

14.5.7. Rest of Asia Pacific

15. Latin America Pompe Disease Therapeutics Market Analysis

15.1. Overview

15.1.1. Market Dynamics for Latin America

15.1.1.1. Drivers

15.1.1.2. Restraints

15.1.1.3. Opportunities

15.1.1.4. Trends

15.2. Latin America Pompe Disease Therapeutics Market, by Therapy Type, 2019-2032(US$ Mn)

15.2.1. Overview

15.2.2. SRC Analysis

15.3. Latin America Pompe Disease Therapeutics Market, by Route of Administration, 2019-2032(US$ Mn)

15.3.1. Overview

15.3.2. SRC Analysis

15.4. Latin America Pompe Disease Therapeutics Market, by End-User, 2019-2032(US$ Mn)

15.4.1. Overview

15.4.2. SRC Analysis

15.5. Latin America Pompe Disease Therapeutics Market, by Country, 2019-2032 (US$ Mn)

15.5.1. Latin America Pompe Disease Therapeutics Market, by Country, 2023 Vs 2032 (in%)

15.5.2. Brazil

15.5.3. Argentina

15.5.4. Rest of Latin America

16. Middle East Pompe Disease Therapeutics Market Analysis

16.1. Overview

16.1.1. Market Dynamics for Middle East

16.1.1.1. Drivers

16.1.1.2. Restraints

16.1.1.3. Opportunities

16.1.1.4. Trends

16.2. Middle East Pompe Disease Therapeutics Market, by Therapy Type, 2019-2032(US$ Mn)

16.2.1. Overview

16.2.2. SRC Analysis

16.3. Middle East Pompe Disease Therapeutics Market, by Route of Administration, 2019-2032(US$ Mn)

16.3.1. Overview

16.3.2. SRC Analysis

16.4. Middle East Pompe Disease Therapeutics Market, by End-User, 2019-2032(US$ Mn)

16.4.1. Overview

16.4.2. SRC Analysis

16.5. Middle East Pompe Disease Therapeutics Market, by Country, 2019-2032 (US$ Mn)

16.5.1. Middle East Pompe Disease Therapeutics Market, by Country, 2023 Vs 2032 (in%)

16.5.2. UAE

16.5.3. Saudi Arabia

16.5.4. Rest of Middle East

17. Africa Pompe Disease Therapeutics Market Analysis

17.1. Overview

17.1.1. Market Dynamics for Africa

17.1.1.1. Drivers

17.1.1.2. Restraints

17.1.1.3. Opportunities

17.1.1.4. Trends

17.2. Africa Pompe Disease Therapeutics Market, by Therapy Type, 2019-2032(US$ Mn)

17.2.1. Overview

17.2.2. SRC Analysis

17.3. Africa Pompe Disease Therapeutics Market, by Route of Administration, 2019-2032(US$ Mn)

17.3.1. Overview

17.3.2. SRC Analysis

17.4. Africa Pompe Disease Therapeutics Market, by End-User, 2019-2032(US$ Mn)

17.4.1. Overview

17.4.2. SRC Analysis

17.5. Africa Pompe Disease Therapeutics Market, by Country, 2019-2032 (US$ Mn)

17.5.1. Africa Pompe Disease Therapeutics Market, by Country, 2023 Vs 2032 (in%)

17.5.2. South Africa

17.5.3. Egypt

17.5.4. Rest of Africa

18. Company Profiles

18.1. Amicus Therapeutics, Inc. (U.S.)

18.1.1. Company Overview

18.1.2. Products/Services Portfolio

18.1.3. Geographical Presence

18.1.4. SWOT Analysis

18.1.5. Financial Summary

18.1.5.1. Market Revenue and Net Profit (2019-2023)

18.1.5.2. Business Segment Revenue Analysis

18.1.5.3. Geographical Revenue Analysis

18.2. Audentes Therapeutics (U.S.)

18.3. Novartis AG (Switzerland)

18.4. Fresenius Kabi AG (Germany)

18.5. Akorn Incorporated (U.S.)

18.6. Teva Pharmaceutical Industries Ltd (Israel)

18.7. Mylan N.V (U.S.)

18.8. Johnsons & Johnsons Services Inc (U.S.)

18.9. F. Hoffman-La Roche Ltd. (Switzerland)

18.10. Danaher (U.S.)

18.11. B.D. (U.S.)

18.12. Chembio Diagnostics (U.S.)

18.13. EKF Diagnostics (U.K.)

18.14. Trinity Biotech plc (Ireland)

18.15. Instrumentation Laboratory (U.S.)

18.16. Nova Biomedical (U.S.)

18.17. PTS Diagnostics (U.S.)

18.18. Sekisui Diagnostics (U.S.)

18.19. Thermo Fisher Scientific (U.S.)

18.20. bioMérieux S.A. (France)

18.21. Others

19. Research Methodology

19.1. Research Methodology

19.2. Phase I – Secondary Research

19.3. Phase II – Data Modelling

19.3.1. Company Share Analysis Model

19.3.2. Revenue Based Modelling

19.4. Phase III – Primary Research

19.5. Research Limitations

19.5.1. Assumptions

List of Figures

FIG. 1 Global Pompe Disease Therapeutics Market: Research Methodology

FIG. 2 Market Size Estimation – Top Down & Bottom up Approach

FIG. 3 Global Pompe Disease Therapeutics Market Segmentation

FIG. 4 Global Pompe Disease Therapeutics Market, by Therapy Type, 2023 (US$ Mn)

FIG. 5 Global Pompe Disease Therapeutics Market, by Route of Administration, 2023 (US$ Mn)

FIG. 6 Global Pompe Disease Therapeutics Market, by End-User, 2023 (US$ Mn)

FIG. 7 Global Pompe Disease Therapeutics Market, by Geography, 2023 (US$ Mn)

FIG. 8 Attractive Investment Proposition, by Therapy Type, 2023

FIG. 9 Attractive Investment Proposition, by Route of Administration, 2023

FIG. 10 Attractive Investment Proposition, by End-User, 2023

FIG. 11 Attractive Investment Proposition, by Geography, 2023

FIG. 12 Global Market Share Analysis of Key Pompe Disease Therapeutics Market Manufacturers, 2023

FIG. 13 Global Market Positioning of Key Pompe Disease Therapeutics Market Manufacturers, 2023

FIG. 14 Global Pompe Disease Therapeutics Market Value Contribution, By Therapy Type, 2023 & 2032 (Value %)

FIG. 15 Global Pompe Disease Therapeutics Market, by Enzyme Replacement Therapy (ERT), Value, 2019-2032 (US$ Mn)

FIG. 16 Global Pompe Disease Therapeutics Market, by Gene Therapy, Value, 2019-2032 (US$ Mn)

FIG. 17 Global Pompe Disease Therapeutics Market, by Small Molecule Therapies, Value, 2019-2032 (US$ Mn)

FIG. 18 Global Pompe Disease Therapeutics Market, by Supportive Therapies, Value, 2019-2032 (US$ Mn)

FIG. 19 Global Pompe Disease Therapeutics Market Value Contribution, By Route of Administration, 2023 & 2032 (Value %)

FIG. 20 Global Pompe Disease Therapeutics Market, by Intravenous (IV) Administration, Value, 2019-2032 (US$ Mn)

FIG. 21 Global Pompe Disease Therapeutics Market, by Oral Administration, Value, 2019-2032 (US$ Mn)

FIG. 22 Global Pompe Disease Therapeutics Market Value Contribution, By End-User, 2023 & 2032 (Value %)

FIG. 23 Global Pompe Disease Therapeutics Market, by Hospitals and Clinics, Value, 2019-2032 (US$ Mn)

FIG. 24 Global Pompe Disease Therapeutics Market, by Specialty Clinics, Value, 2019-2032 (US$ Mn)

FIG. 25 Global Pompe Disease Therapeutics Market, by Home Care Settings, Value, 2019-2032 (US$ Mn)

FIG. 26 North America Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 27 U.S. Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 28 Canada Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 29 Mexico Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 30 Europe Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 31 Germany Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 32 France Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 33 U.K. Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 34 Italy Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 35 Spain Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 36 Benelux Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 37 Russia Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 38 Rest of Europe Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 39 Asia Pacific Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 40 China Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 41 Japan Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 42 India Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 43 South Korea Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 44 South-East Asia Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 45 Rest of Asia Pacific Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 46 Latin America Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 47 Brazil Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 48 Argentina Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 49 Rest of Latin America Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 50 Middle East Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 51 UAE Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 52 Saudi Arabia Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 53 Rest of Middle East Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 54 Africa Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 55 South Africa Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 56 Egypt Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

FIG. 57 Rest of Africa Pompe Disease Therapeutics Market, 2019-2032 (US$ Mn)

List of Tables

TABLE 1 Market Snapshot: Global Pompe Disease Therapeutics Market

TABLE 2 Global Pompe Disease Therapeutics Market: Market Drivers Impact Analysis

TABLE 3 Global Pompe Disease Therapeutics Market: Market Restraints Impact Analysis

TABLE 4 Global Pompe Disease Therapeutics Market, by Competitive Benchmarking, 2023

TABLE 5 Global Pompe Disease Therapeutics Market, by Geographical Presence Analysis, 2023

TABLE 6 Global Pompe Disease Therapeutics Market, by Key Strategies Analysis, 2023

TABLE 7 Global Pompe Disease Therapeutics Market, by Enzyme Replacement Therapy (ERT), By Region, 2019-2023 (US$ Mn)

TABLE 8 Global Pompe Disease Therapeutics Market, by Enzyme Replacement Therapy (ERT), By Region, 2024-2032 (US$ Mn)

TABLE 9 Global Pompe Disease Therapeutics Market, by Gene Therapy, By Region, 2019-2023 (US$ Mn)

TABLE 10 Global Pompe Disease Therapeutics Market, by Gene Therapy, By Region, 2024-2032 (US$ Mn)

TABLE 11 Global Pompe Disease Therapeutics Market, by Small Molecule Therapies, By Region, 2019-2023 (US$ Mn)

TABLE 12 Global Pompe Disease Therapeutics Market, by Small Molecule Therapies, By Region, 2024-2032 (US$ Mn)

TABLE 13 Global Pompe Disease Therapeutics Market, by Supportive Therapies, By Region, 2019-2023 (US$ Mn)

TABLE 14 Global Pompe Disease Therapeutics Market, by Supportive Therapies, By Region, 2024-2032 (US$ Mn)

TABLE 15 Global Pompe Disease Therapeutics Market, by Intravenous (IV) Administration, By Region, 2019-2023 (US$ Mn)

TABLE 16 Global Pompe Disease Therapeutics Market, by Intravenous (IV) Administration, By Region, 2024-2032 (US$ Mn)

TABLE 17 Global Pompe Disease Therapeutics Market, by Oral Administration, By Region, 2019-2023 (US$ Mn)

TABLE 18 Global Pompe Disease Therapeutics Market, by Oral Administration, By Region, 2024-2032 (US$ Mn)

TABLE 19 Global Pompe Disease Therapeutics Market, by Hospitals and Clinics, By Region, 2019-2023 (US$ Mn)

TABLE 20 Global Pompe Disease Therapeutics Market, by Hospitals and Clinics, By Region, 2024-2032 (US$ Mn)

TABLE 21 Global Pompe Disease Therapeutics Market, by Specialty Clinics, By Region, 2019-2023 (US$ Mn)

TABLE 22 Global Pompe Disease Therapeutics Market, by Specialty Clinics, By Region, 2024-2032 (US$ Mn)

TABLE 23 Global Pompe Disease Therapeutics Market, by Home Care Settings, By Region, 2019-2023 (US$ Mn)

TABLE 24 Global Pompe Disease Therapeutics Market, by Home Care Settings, By Region, 2024-2032 (US$ Mn)

TABLE 25 Global Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 26 Global Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 27 Global Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 28 Global Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 29 Global Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 30 Global Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 31 Global Pompe Disease Therapeutics Market, by Region, 2019-2023 (US$ Mn)

TABLE 32 Global Pompe Disease Therapeutics Market, by Region, 2024-2032 (US$ Mn)

TABLE 33 North America Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 34 North America Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 35 North America Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 36 North America Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 37 North America Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 38 North America Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 39 North America Pompe Disease Therapeutics Market, by Country, 2019-2023 (US$ Mn)

TABLE 40 North America Pompe Disease Therapeutics Market, by Country, 2024-2032 (US$ Mn)

TABLE 41 United States Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 42 United States Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 43 United States Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 44 United States Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 45 United States Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 46 United States Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 47 Canada Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 48 Canada Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 49 Canada Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 50 Canada Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 51 Canada Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 52 Canada Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 53 Mexico Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 54 Mexico Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 55 Mexico Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 56 Mexico Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 57 Mexico Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 58 Mexico Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 59 Europe Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 60 Europe Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 61 Europe Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 62 Europe Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 63 Europe Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 64 Europe Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 65 Europe Pompe Disease Therapeutics Market, by Country, 2019-2023 (US$ Mn)

TABLE 66 Europe Pompe Disease Therapeutics Market, by Country, 2024-2032 (US$ Mn)

TABLE 67 Germany Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 68 Germany Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 69 Germany Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 70 Germany Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 71 Germany Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 72 Germany Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 73 France Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 74 France Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 75 France Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 76 France Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 77 France Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 78 France Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 79 United Kingdom Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 80 United Kingdom Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 81 United Kingdom Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 82 United Kingdom Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 83 United Kingdom Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 84 United Kingdom Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 85 Italy Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 86 Italy Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 87 Italy Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 88 Italy Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 89 Italy Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 90 Italy Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 91 Spain Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 92 Spain Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 93 Spain Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 94 Spain Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 95 Spain Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 96 Spain Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 97 Benelux Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 98 Benelux Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 99 Benelux Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 100 Benelux Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 101 Benelux Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 102 Benelux Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 103 Russia Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 104 Russia Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 105 Russia Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 106 Russia Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 107 Russia Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 108 Russia Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 109 Rest of Europe Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 110 Rest of Europe Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 111 Rest of Europe Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 112 Rest of Europe Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 113 Rest of Europe Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 114 Rest of Europe Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 115 Asia Pacific Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 116 Asia Pacific Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 117 Asia Pacific Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 118 Asia Pacific Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 119 Asia Pacific Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 120 Asia Pacific Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 121 China Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 122 China Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 123 China Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 124 China Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 125 China Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 126 China Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 127 Japan Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 128 Japan Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 129 Japan Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 130 Japan Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 131 Japan Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 132 Japan Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 133 India Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 134 India Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 135 India Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 136 India Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 137 India Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 138 India Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 139 South Korea Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 140 South Korea Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 141 South Korea Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 142 South Korea Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 143 South Korea Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 144 South Korea Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 145 South-East Asia Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 146 South-East Asia Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 147 South-East Asia Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 148 South-East Asia Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 149 South-East Asia Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 150 South-East Asia Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 151 Rest of Asia Pacific Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 152 Rest of Asia Pacific Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 153 Rest of Asia Pacific Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 154 Rest of Asia Pacific Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 155 Rest of Asia Pacific Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 156 Rest of Asia Pacific Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 157 Latin America Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 158 Latin America Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 159 Latin America Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 160 Latin America Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 161 Latin America Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 162 Latin America Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 163 Brazil Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 164 Brazil Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 165 Brazil Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 166 Brazil Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 167 Brazil Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 168 Brazil Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 169 Argentina Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 170 Argentina Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 171 Argentina Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 172 Argentina Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 173 Argentina Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 174 Argentina Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 175 Rest of Latin America Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 176 Rest of Latin America Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 177 Rest of Latin America Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 178 Rest of Latin America Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 179 Rest of Latin America Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 180 Rest of Latin America Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 181 Middle East Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 182 Middle East Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 183 Middle East Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 184 Middle East Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 185 Middle East Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 186 Middle East Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 187 UAE Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 188 UAE Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 189 UAE Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 190 UAE Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 191 UAE Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 192 UAE Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 193 Saudi Arabia Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 194 Saudi Arabia Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 195 Saudi Arabia Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 196 Saudi Arabia Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 197 Saudi Arabia Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 198 Saudi Arabia Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 199 Rest of Middle East Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 200 Rest of Middle East Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 201 Rest of Middle East Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 202 Rest of Middle East Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 203 Rest of Middle East Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 204 Rest of Middle East Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 205 Africa Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 206 Africa Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 207 Africa Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 208 Africa Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 209 Africa Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 210 Africa Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 211 South Africa Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 212 South Africa Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 213 South Africa Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 214 South Africa Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 215 South Africa Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 216 South Africa Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 217 Egypt Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 218 Egypt Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 219 Egypt Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 220 Egypt Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 221 Egypt Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 222 Egypt Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

TABLE 223 Rest of Africa Pompe Disease Therapeutics Market, by Therapy Type, 2019-2023 (US$ Mn)

TABLE 224 Rest of Africa Pompe Disease Therapeutics Market, by Therapy Type, 2024-2032 (US$ Mn)

TABLE 225 Rest of Africa Pompe Disease Therapeutics Market, by Route of Administration, 2019-2023 (US$ Mn)

TABLE 226 Rest of Africa Pompe Disease Therapeutics Market, by Route of Administration, 2024-2032 (US$ Mn)

TABLE 227 Rest of Africa Pompe Disease Therapeutics Market, by End-User, 2019-2023 (US$ Mn)

TABLE 228 Rest of Africa Pompe Disease Therapeutics Market, by End-User, 2024-2032 (US$ Mn)

Frequently Asked Questions:

How much does the global market currently hold for Pompe disease therapeutics?

In 2023, the Pompe disease therapeutics market was estimated to be worth USD 1584.2 million.

What is the Pompe disease therapeutics market’s projected growth rate between 2024 and 2032?

The Pompe disease therapeutics market is anticipated to increase at a CAGR of 5.00% from 2024 to 2032, reaching USD 2457.61 million in 2032.

In terms of the therapy type, which market category is leading?

Enzyme replacement therapy (ERT) is the most popular category.

Regarding the route of administration, which market category is in the lead?

The noteworthy route of the administration segment is oral administration.

Which end-user category is anticipated to grow at the fastest rate throughout the projected period?

During the forecast timeframe, the hospitals and clinics are expected to have the strongest estimated CAGR.

In which region is the market for Pompe disease therapeutics expanding?

Asia Pacific ruled the Pompe disease therapeutics market.

Who are the main players in the global Pompe disease therapeutics industry?

The top players include Amicus Therapeutics, Inc. (U.S.), Audentes Therapeutics (U.S.), Novartis AG (Switzerland), Fresenius Kabi AG (Germany), Akorn Incorporated (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Mylan N.V (U.S.), Johnsons & Johnsons Services Inc (U.S.), F. Hoffman-La Roche Ltd. (Switzerland), Danaher (U.S.), B.D. (U.S.), Chembio Diagnostics (U.S.), EKF Diagnostics (U.K.), Trinity Biotech plc (Ireland), Instrumentation Laboratory (U.S.), Nova Biomedical (U.S.), PTS Diagnostics (U.S.), Sekisui Diagnostics (U.S.), Thermo Fisher Scientific (U.S.), bioMérieux S.A. (France), and others.

Which market factors are the primary drivers of the Pompe disease therapeutics industry?

The necessity for treatment methods for Pompe disease is being increased by the growing number of newborn screening initiatives, the financing for biotechnology, and the latest developments in drug delivery platforms.

What main market challenges prevent the growth of the Pompe disease therapeutics sector?

The major challenges to the growth of the pompe disease therapeutics market are genetic diversity in the condition, limited accessibility in less wealthy countries, and financial limitations in healthcare systems.

What are the main market opportunities for the Pompe disease therapeutics sector?

Numerous factors, such as an increasing number in genetic disorders globally, collaborations with research centers, and discoveries in biopharmaceutical production, are contributing to the Pompe therapeutics market’s expansion.

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$7699

Let us help you

MIKE, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –